@article {Pittock10.1212 / WNL。0000000000207770,作者= {Rioghna R Pittock耶利米Aakre安娜米卡斯蒂略和Vijay K Ramanan沃尔特·K·克雷默和克利福德·R·杰克和Prashanthi Vemuri Val j·劳和David Knopman和罗纳德·C彼得森和乔纳森Graff-Radford和玛丽亚Vassilaki}, title ={种抗体治疗的资格以人群为基础的研究认知老化},elocation-id = {10.1212 / WNL。={2023}0000000000207770},年,doi = {10.1212 / WNL。出版商0000000000207770}= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={背景和目标的治疗选择{\ textquoteright}年代老年痴呆症(广告)首页是有限的,主要关注治疗症状和提高生活质量。lecanemab,最近一个anti-beta淀粉样蛋白单克隆抗体(mab),由美国食品和药物管理局获得加速批准治疗的早期阶段biomarker-confirmed症状广告。额外anti-beta淀粉样马伯,aducanumab,于2021年获得批准,更可能会出现在不久的将来。淀粉样蛋白研究的适用性和普遍性anti-beta马伯合格标准与生物标志物在成年人一般人群一直缺乏。研究{\ textquoteright}年代主要目的是应用临床试验合格标准lecanemab治疗与早期广告参与者以人群为基础的梅奥诊所的研究衰老(MCSA)和评估种抗体治疗的普遍性。二次研究的目的是应用aducanumab治疗的临床试验合格标准MCSA参与者。目前的横断面研究方法旨在应用临床试验合格标准lecanemab和aducanumab治疗与早期参与者以人群为基础的广告MCSA和评估种抗体治疗的普遍性。结果二百三十七MCSA参与者(平均年龄(标准差)80.9(6.3)年,男性和97.5 \ 54.9 \ % %白色)与轻度认知障碍(MCI)或轻度痴呆和脑淀粉样负担增加了加以宠物组成研究样本。 Lecanemab trial{\textquoteright}s inclusion criteria reduced the study sample to 112 (47.3\% of 237) participants. The trial{\textquoteright}s exclusion criteria further narrowed the number of potentially eligible to 19 (overall 8\% of 237). Modifying the exclusion criteria to include all participants with MCI (instead of applying additional cognitive criteria) resulted in 17.4\% of participants with MCI being eligible for lecanemab treatment. One hundred and four participants (43.9\% of 237) fulfilled the aducanumab clinical trial{\textquoteright}s inclusion criteria. The aducanumab trial{\textquoteright}s exclusion criteria further reduced the number of available participants, narrowing those eligible to 12 (5.1\% of 237). Common exclusions related to other chronic conditions and neuroimaging findings.Discussion Findings estimate the limited eligibility in typical older adults with cognitive impairment for anti-beta amyloid mAbs.}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/early/2023/08/16/WNL.0000000000207770}, eprint = {//www.ez-admanager.com/content/early/2023/08/16/WNL.0000000000207770.full.pdf}, journal = {Neurology} }